Compare LQDA & APAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LQDA | APAM |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 2018 | 2013 |
| Metric | LQDA | APAM |
|---|---|---|
| Price | $34.21 | $41.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $37.40 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 1.1M | 507.5K |
| Earning Date | 11-03-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 8.71% |
| EPS Growth | N/A | ★ 2.95 |
| EPS | N/A | ★ 3.71 |
| Revenue | $69,216,000.00 | ★ $1,158,234,000.00 |
| Revenue This Year | $994.17 | $8.38 |
| Revenue Next Year | $169.25 | $6.56 |
| P/E Ratio | ★ N/A | $11.25 |
| Revenue Growth | ★ 343.41 | 8.88 |
| 52 Week Low | $11.26 | $32.75 |
| 52 Week High | $36.41 | $48.50 |
| Indicator | LQDA | APAM |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 40.79 |
| Support Level | $33.45 | $41.50 |
| Resistance Level | $36.60 | $42.04 |
| Average True Range (ATR) | 1.41 | 0.69 |
| MACD | -0.25 | 0.05 |
| Stochastic Oscillator | 47.88 | 47.79 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. In addition to its equity strategies, customers may invest in a fixed-income strategy. Strategies are often distributed to customers ranging from retail investors to institutional investors through specialized channels.